Next Phase Newsletter

An angel investor group looks to invest in companies that help solve societal problems and will either invest in an existing company or help form a company around a technology that addresses a need. With a current focus on healthcare, the firm looks for technologies with a social impact, such as those addressing chronic pain management, the opioid crisis or issues facing the aging population. The firm invests in seed/angel rounds and may invest in follow on rounds, generally investing between $20K-300K. The firm will lead a seed round, or co-invest in an angel round. The firm is seeking to invest in companies with high-growth potential in the US, but will invest in Canada as well. The firm will also partner with medical societies or academic centers to transfer technologies into new ventures.

The firm is opportunistic with regards to sector and indication, and will invest in therapeutics, devices, diagnostics or digital health companies in any indication that meets their mission of social impact and investment thesis around high growth. The firm has historically invested in companies within neuroscience but is also open to other indications such as cardiovascular disease and diabetes. The firm generally takes a board or observer seat after investing, and can provide interim management support as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm with headquarters in Germany and an additional office in Boston, MA and is allocating their funds primarily into companies in Europe and North America. There is an approximately 50:50 split between traditional equity investments and venture creation, the initial investment size is in the range from $1-5M in the Seed Round and additional $10-15 for subsequent rounds.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm is primarily focused on therapeutics, but is also considering advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. In therapeutics, The firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat, but are also open to joining strong syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com

An investment group that was founded in 2005 and is headquartered in New York with other offices in Boston, Silicon Valley and Texas. The group currently invests out of its angel network and venture funds. The group has managed 3 venture funds. The group’s angel network has 320 members, of which 100 are life science investors. The group invests in companies with a female founder or CEO, or with women in other C-level positions or with at least 10% of equity owned by women. The group prefers to invest in companies with a valuation under $5 million; the group’s first-round equity investments generally range from $ 0.25 million to $2 million. The group invests in companies based across the US and Canada.

Within the life science sector, the group is highly opportunistic and inclusive when considering opportunities. The group prefers to invest in products that have an addressable market of over $1 billion. The group is more interested in large marketplaces such as the cardiovascular space. In terms of validation, the group prefers to invest in device companies with positive in vitro data and ideally in vivo data; diagnostic companies with strong retrospective and ideally prospective, data; and therapeutics companies with data showing efficacy in animal models. As the group is interested in products with a shorter path to market, the group primarily invests in healthcare IT (including software-based diagnostic platforms) and medical devices.

The group only backs privately held companies in which women occupy key roles as managers, founders or equity owners, and prefers to back management teams with a strong scientific background. The group is looking for life science companies with protectable IP, articulated pathways for regulatory and payer approval, clear milestones, and in which the amount of capital required to reach the marketplace can be clearly stated. The group prefers to invest in life science companies that can reach market within 3-5 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of-concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Established 2015 and headquartered in the UK, the firm is the corporate venture capital arm of a global generic manufacturer that is listed on the London Stock Exchange. The firm can invest up to $5M to a round and will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. The firm is open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

The private equity subsidiary of a European banking group carries out venture capital, growth capital and buyout activities. The firm supports business leaders at all stages of their companies’ development, from seed phase to buyout, by providing them with the means and the time required to implement their transformational projects. Using its own funds (€3.0 billion), the firm makes investments tailored to the time horizons and growth strategies of the companies in which it invests, whether in France, Canada, the United States, Germany or Switzerland. The firm makes equity investments in progressive stages, ranging up to $10m and typically leads the round – although the firm is open to co-investing.

The firm is interested in all areas of technology, and devotes about half of its Fund to healthcare and the other half to the Digital sector covering IT, Telecom, etc. The firm is also interested in novel healthcare IT opportunities such as applications of AI and machine learning in healthcare. The firm seeks highly differentiated, disruptive technology; and does not invest in “me-too” products. 20% of the fund’s investments are in pre-revenue companies; 40% are in companies that are revenue-generating but not yet at break-even, and 40% are in profitable companies.

The firm seeks disruptive technology companies led by high-quality management teams, and prefers to work with managers who have had previous successes in technology start-ups. Additionally, the firm welcome the opportunity to co-invest with top tier investors. The firm will want to have a representation on the Board of Directors.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A corporate venture arm of a diversified business based in Asia is focused on three primary sectors, and one of them includes healthcare. The team has offices in key hub cities in USA, and the fund has an evergreen structure looking to allocate between $1-3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.